



Ultragenyx Announces First Patient Dosed in Pivotal Phase 2/3 Clinical Study of Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta

April 20, 2022

Global study will evaluate UX143 in pediatric and young adult patients ages 5 to